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A number of studies have shown that proinﬂammatory cytokines have important roles in determining the development of
microvascular diabetic complications, including nephropathy. Inﬂammatory biomarkers should be useful for diagnosis or
monitoring of diabetic nephropathy. Mindin (spondin 2) is a member of the mindin -/F-spondin family of secreted extracellular
matrix (ECM) proteins. Recent studies showed that mindin is essential for initiation of innate immune response and represents
a unique pattern-recognition molecule in the ECM. Previously, we demonstrated that the levels of urinary mindin in patients
with type 2 diabetes were higher than those in healthy individuals. We propose that urinary mindin is a potent biomarker for the
development of diabetic nephropathy.
1.Introduction
Diabetic nephropathy is a major cause of end-stage kidney
disease (ESKD) in the United States, Japan, and most of
Europe [1]. Although the etiology of this insidious disorder
is not well understood, hyperglycemia and hypertension may
play pivotal roles in the pathogenesis of diabetic nephropa-
thy. Actually, almost 30% of diabetic patients develop dia-
betic nephropathy despite strict blood glucose and/or blood
pressure control [2]. Chronic low-grade inﬂammation (so-
called microinﬂammation) has been found to play roles in
the pathogenesis of diabetes [3, 4] and has been identiﬁed as
ariskfactorforthedevelopmentofdiabetes[5,6].Moreover,
diabetes has been proposed as a disease of the innate
immune system [7]. In addition, the studies in recent years
have shown that inﬂammation and inﬂammatory cytokines
are determinants in the development of microvascular
diabetic complications such as neuropathy, retinopathy, and
nephropathy [8–11]. In 1991, Hasegawa et al. reported that
glomerular basement membranes from diabetic rats induced
signiﬁcantly greater amounts of tumor necrosis factor-α
(TNF-α) and interleukin-1 (IL-1) in cultured peritoneal
macrophages than when these cells were incubated with
basement membranes from nondiabetic rats [12]. Based on
these ﬁndings, the authors suggested for the ﬁrst time that
inﬂammatory cytokines may participate in the pathogenesis
ofdiabeticnephropathy[12].Atpresent,anumberofclinical
studies have suggested relationships between inﬂammatory
cytokines and diabetic nephropathy [13, 14]. Inﬂammatory
cytokines, that is, IL-1, interleukin-6 (IL-6), and interleukin-
18 (IL-18) [15, 16], vascular endothelial growth factor
(VEGF) [17, 18], monocyte chemoattractant protein-1
(MCP-1) [19, 20], and transforming growth factor-β (TGF-
β)[ 21], as well as TNF-α [22–24] ,a r ei n v o l v e di nt h e
development and progression of diabetic nephropathy. It has
been demonstrated that endothelial, mesangial, glomerular,
and tubular epithelial cells can synthesize inﬂammatory
cytokines, which have signiﬁcant renal eﬀects.
To survey the glomerular gene expression proﬁle in type
2diabetes,weperformedamicroarrayanalysisusingisolated
glomeruli from diabetic KK/Ta mice [25]. We observed
signiﬁcant diﬀerences in the expression of immune response
and inﬂammatory-related genes. Among them, mindin (also
called spondin 2, SPON2) mRNA was signiﬁcantly upreg-
ulated. The present paper focuses on mindin as a urinary
marker in diabetic nephropathy.2 Experimental Diabetes Research
Table 1: Roles of mindin in immune response and inﬂammation.
Authors Year Role of mindin Reference
He et al. 2004 Pattern recognition molecule for microbial pathogens [26]
Jia et al. 2005 Integrin ligand for inﬂammatory cell recruitment [27]
Li et al. 2006 Regulating Rho GTPase expression in DCs and DC priming of T lymphocytes [28]
Jia et al. 2008 Immune-enhancing agent in inﬂuenza infection [29]
Li et al. 2009 Traﬃcking of normal eosinophils into the airspace and the pathogenesis of allergic airway disease [30]
Guleng et al. 2010 Activation of NF-kappaB in a TLR-9 mediated manner during colitis [31]
2. Molecular Structureof Mindin
Mindin is a highly conserved extracellular matrix (ECM)
protein that is abundantly expressed in the spleen and
lymph nodes [26]. It is a member of the mindin-F-spondin
(FS) family of secreted ECM proteins that also includes
mammalian FS, zebraﬁsh mindin 1 and mindin 2, and
Drosophila M-spondin [32–37]. Mindin was initially identi-
ﬁed in zebraﬁsh and was observed to accumulate selectively
in the basal lamina [33]. Subsequently, the genes encoding
rat and human mindin were cloned [35, 36]. Mouse Spon2
cDNA encodes an open reading frame of 330 amino acids
with a calculated molecular mass of 36kDa. Rat mindin is
a secreted protein that promotes adhesion and outgrowth of
hippocampal embryonic neurons in vitro [35]. All members
of the mindin-FS family share three structural domains.
Two domains, FS1 and FS2 (for F-spondin), are unique to
this family. A third domain, called thrombospondin-type
1 repeats (TSRs), is found in a large group of proteins
including thrombospondins, the semaphoring 5 family,
and the ADAM (disintegrin and metalloproteinase) protein
family [38]. The crystalstructureof the FS domain of human
mindin was demonstrated to be the domain that mediates
integrin binding [39]. Remarkably, mindin also functions as
a pattern recognition molecule for microbial pathogens [26]
and as an integrin ligand for inﬂammatory cell recruitment
and T-cell priming [27, 28, 30].
3. Role of MindininInﬂammatoryDisease
As shown in Table 1, mindin has been studied as essential
factor in immune response. He et al. measured serum con-
centrationsofTNFandIL-6toassaycytokineconcentrations
in mindin-deﬁcient mice treated with lipopolysaccharide
(LPS) [26]. The serum concentrations of these cytokines in
control mice treated with LPS were substantially increased.
In contrast, the serum concentrations of these cytokines
in the mindin-deﬁcient mice were only slightly increased
after LPS challenge, indicating that mindin is essential for
the in vivo production of inﬂammatory cytokines during
endotoxin-inducedsepticshock.Macrophagesandmastcells
from mindin-deﬁcient mice show defective responses to a
broad spectrum of microbial stimuli. Mindin recognizes LPS
through its TSR domain [39]. Mindin also functions as
an opsonin for macrophage phagocytosis of bacteria [26].
Mice lacking mindin exhibit defective clearance of inﬂuenza
virus,whereasmindin-deﬁcientmacrophagesshowimpaired
activation following inﬂuenza infection [29]. Thus, mindin
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Figure 1: Mindin protein expression in glomeruli of 20-week-old
KK/Ta mice. Double-immunohistochemical staining for mindin
(brown; arrow) and WT1 (purple; arrowhead, podocyte nucleus
marker) in kidney sections from mice with HD at 20 weeks of
age. Counterstaining with hematoxylin (blue; asterisk) was used to
visualize nuclei.
is a pattern recognition molecule that is critical for initiating
innate immune responses such as Toll-like receptor 4 (TLR4)
[29, 40]( Figure 2). Guleng et al. demonstrated that mRNA
expression of mindin is upregulated during dextran sulfate
sodium-induced acute intestinal inﬂammation and is also
upregulated by CpG-ODN (a known TLR-9 ligand) stim-
ulation in vitro. Moreover, mindin induces nuclear-factor-
(NF-) κB promoter activation in a TLR-9 mediated manner
[31].
As mentioned above, our microarray data suggested
a relationship between mindin and diabetic nephropathy.
We focused on mindin expression in the glomeruli and
attempted to determine whether an increase in urinary
mindin was associated with the development of diabetic
nephropathy.
4. MindinandDiabeticNephropathy
In contrast to the immune reaction in response to acute
infection or inﬂammation, the immune processes in chronic
diseasessuchasdiabeticnephropathycanbesmolderingpro-
cessesthatarediﬃculttodetect.Developmentofadiagnostic
test, more convenient and reliable than those currently used,
wouldthereforebe highlydesirable.Urine iseasilyaccessible,Experimental Diabetes Research 3
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Figure 2: Mindin as an essential factor in immune response. Mindin has an important role in both innate and adaptive immunity.
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Figure 3: Urinary mindin secretion in patients with diabetic nephropathy by western blot analysis. Healthy control (n = 3),
Normoalbuminuria (n = 4): <30mg albumin/g creatinine, Microalbuminuria (n = 4): 30–300mg albumin/g creatinine, Proteinuria
(n = 3): >300mg albumin/g creatinine, Renal failure (n = 4); ∗∗∗∗P<0.0001 versus healthy control; ∗∗P<0.01 versus healthy control;
∗P<0.05 versus healthy control.
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Figure 4: The hypothesis concerning the role of mindin in diabetic nephropathy. Mindin might be related to podocyte injury in diabetic
nephropathy and regulate not only inﬂammation but also cytoskeletal change via integrin.4 Experimental Diabetes Research
andtherefore,asa diagnostic medium allowsfornoninvasive
detection of biomarkers. With 70% of urinary proteins
originating from the kidney and urinary tract, and 30%
being ﬁltered by the kidney, urinary biomarkers are likely
to be linked to renal dysfunction or systemic changes [41].
Urinary albumin, the current gold standard, is known that
signiﬁcant structural changes have already appeared even at
the stage of microalbuminuria in type 2 diabetes patients.
Thus,itisnecessarytodevelopamoresensitivemeasurement
for detecting the early stage of renal injury in patients
with diabetic nephropathy. Inﬂammatory markers should be
useful biomarkers for diagnosis or monitoring of diabetic
complications, particularly kidney disease. However, the
sensitivity of these markers compared with albumin requires
further investigation. We dissected isolated glomeruli from
three 20-week-old KK/Ta mice fed a high-calorie diet (HC)
or a standard diet (SD). The inbred mouse strain KK/Ta,
established as a diabetic strain in Japan, spontaneously
exhibitscharacteristicsoftype2diabetesassociatedwithfast-
ing hyperglycemia, glucose intolerance, hyperinsulinemia,
mild obesity, dyslipidemia, and albuminuria. Renal lesions
in KK/Ta mice closely resemble those in the early stage of
human diabetic nephropathy. The albumin/creatinine ratio
(ACR) in male KK/Ta mice at 16 weeks of age is 150–
200mg/gCr. KK/Ta mice glomeruli show diﬀuse hyperplasia
in the glomerular mesangial areas with mild mesangial
cell proliferation [42]. Immunohistological studies show an
intense, speciﬁc ﬂuorescence for albumin and γ-globulin
along the glomerular capillary walls. Therefore, KK/Ta mice
areconsideredtoprovideasuitablemodelfortype2diabetes
and the early stage of diabetic nephropathy in humans.
Mindin expression was examined using real-time PCR,
western blot analysis, and immunohistochemical staining of
the glomeruli (Figure 1), as well as cultured podocytes and
urinesamplesofbothmiceandhumans.Themindinprotein
expression levels in mice were localized in the podocytes,
and their levels in the glomeruli were increased in the HC
g r o u pc o m p a r e dw i t ht h eS Dg r o u p[ 25]. We also examined
podocyte cultures incubated in high glucose (HG). Mindin
wasdetectedinpodocyteculturesupernatantsanditsexpres-
sion levels under HG stimulation were signiﬁcantly higher
than those under normal glucose stimulation. Therefore, we
examined the urinary secretion of mindin. Urinary mindin
expression levels in the HC group were already signiﬁcantly
higher than those in the SD group at 16 weeks of age. The
urinary mindin level seems to be increased earlier compared
with the ACR. Furthermore, mindin was also detectable in
human urine. Urinary mindin expression in patients with
type 2 diabetes increased compared with that in healthy
individuals, reﬂecting the stage of diabetic nephropathy
(Figure 3).
Podocytes cover the outer aspect of the glomerular base-
mentmembrane(GBM)andformtheﬁnalbarriertoprotein
loss [43]. The podocyte foot process is ﬁxed to the GBM
via α3β1 integrin and α/β dystroglycans, and α3β1 integrin
is the major integrin expressed by podocytes [44–46]. Jia et
al. reported that mindin serves as an integrin ligand [27].
We also found that β1 integrin protein expression increased
in the cultured podocytes stimulated under HG conditions
(data not shown). Moreover, mindin was reported as a
key regulator of Rho GTPase expression. Signaling through
integrinsactivatesRhoGTPases[28].Cytoskeletalchangesof
podocytes regulated by the Rho family are critically involved
in the pathogenesis of glomerular diseases. Mindin should
be produced by damaged podocytes under high glucose
conditions and serve as a biomarker of the progression of
diabetic nephropathy (Figure 4).
5. Conclusion
Increasing evidence indicates that inﬂammatory and
immune response mechanisms may contribute signiﬁcantly
tothedevelopmentandprogressionofdiabeticnephropathy.
Recent studies showed that mindin is essential for the
initiation of immune response and represents a unique
pattern-recognition molecule in the ECM. We focused on
the role of mindin and examined the urinary secretion of
mindin in mice and humans. Mindin could be an early
biomarker of the progression of diabetic nephropathy.
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